This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
A product was about to go generic within the metastatic renal cell carcinoma (mRCC) indication. Our client wished to understand the potential impact of the competitor’s drug going generic on their brand and whether there would be any spill-over effects
Pharma Intelligence Consulting selected a set of historical analog drugs to model past benchmarking.
We adopted five analytical methods to selecting the right analogs:
1) Bivariate analysis 2) Time series progression 3) Unit price differential 4) Market share evolution and 5) Weighted mean prioritization
Our comprehensive market report identified the most appropriate analogs for this therapeutic area and helped the client quantify the relationship between price-volume, and better understand the impact that pricing strategies can have on demand post LOE. Our analysis further outlined the speed and extent to which generic penetration occurs and the spill- over effects on share across the category.
Our market segmentation based on the risk of generic exposure enabled the client to effectively strategize across regions.